Consensus The Chemours Company

Equities

CC

US1638511089

Real-time Estimate Cboe BZX Other stock markets 03:33:51 2024-05-14 pm EDT			5-day change	1st Jan Change
28.92 ^USD	+1.63%		+3.45%	-8.26%

May. 06	Hudson Technologies Signs Licensing Agreement With Chemours	MT
May. 06	Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	MT

Evolution of the average Target Price on The Chemours Company

Price target over the last 5 years

History of analyst recommendation changes

3a10d98a5ddea6.LZy5UQOOXj9bFyfVRdLsRgaA7d0k1AJpgP22tZfenBU.aq_eJHbvKWswdUaEMruVEkDRnL8Vt2MR68Xe4-KO-CVs7cNgXOMkcxJGEw~a37c5415521f7585251dae1a2fd69407

Analyst Recommendations on The Chemours Company

Hudson Technologies Signs Licensing Agreement With Chemours	May. 06	MT
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Monday; Palantir to Advance, Trump Media & Technology Group to Decline	May. 06	MT
BMO Capital Upgrades Chemours to Outperform From Underperform, Raises Price Target to $34 From $19	Apr. 09	MT
UBS Adjusts Chemours Price Target to $28 From $21, Maintains Neutral Rating	Apr. 02	MT
UBS Downgrades Chemours to Neutral From Buy, Cuts Price Target to $21 From $37	Mar. 05	MT
BMO Capital Downgrades Chemours to Underperform From Outperform, Adjusts Price Target to $19 From $45	Mar. 01	MT
RBC Upgrades Chemours to Outperform From Sector Perform, Lifts Price Target to $40 From $28 on Titanium Technologies Recovery, Thermal & Specialized Solutions Strength	Dec. 01	MT
Goldman Sachs Adjusts Chemours' Price Target to $30 From $35, Maintains Neutral Rating	23-10-31	MT
BMO Capital Adjusts Chemours' PT to $39 From $45, Keeps Outperform Rating	23-10-30	MT
Morgan Stanley Cuts Price Target on Chemours to $28 From $33, Maintains Equal-Weight Rating	23-10-30	MT
Barclays Cuts Price Target on Chemours to $28 From $31, Maintains Equal-Weight Rating	23-10-30	MT
RBC Cuts Price Target on Chemours to $28 From $30, Keeps Sector Perform Rating	23-10-30	MT
UBS Cuts Chemours Price Target to $37 From $41, Maintains Buy Rating	23-10-27	MT
RBC Cuts Price Target on Chemours to $30 From $40, Keeps Sector Perform Rating	23-10-23	MT
BofA Securities Adjusts Price Target on Chemours to $32 From $39, Maintains Neutral Rating	23-10-18	MT
UBS Cuts Chemours Price Target to $41 From $47, Maintains Buy Rating	23-10-09	MT
Barclays Adjusts Price Target on Chemours to $31 From $40, Keeps Equalweight Rating	23-10-04	MT
BMO Capital Adjusts Price Target on Chemours to $53 From $64, Maintains Outperform Rating	23-08-02	MT
RBC Boosts Price Target on Chemours to $40 From $37, Maintains Sector Perform Rating	23-07-31	MT
UBS Adjusts Chemours Price Target to $47 From $43, Maintains Buy Rating	23-07-28	MT
Barclays Adjusts Price Target on Chemours Company to $40 From $38, Maintains Equalweight Rating	23-07-11	MT
BofA Securities Downgrades Chemours to Neutral From Buy, Lowers Price Target to $37 From $41	23-06-22	MT
UBS Raises Chemours' Price Target to $43 From $41, Maintains Buy Rating	23-06-13	MT
RBC Lifts Price Target on Chemours to $37 From $36 on Recent PFAS Settlement, Maintains Sector Perform Rating	23-06-09	MT
BMO Capital Adjusts Chemours' Price Target to $64 From $54, Keeps Outperform Rating	23-06-05	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

28.71 USD

Average target price

30.56 USD

Spread / Average Target

+6.43%

High Price Target

38 USD

Spread / Highest target

+32.36%

Low Price Target

25 USD

Spread / Lowest Target

-12.92%

Consensus detail

Consensus revision (last 18 months)

Analysts covering The Chemours Company

BMO Capital
UBS
RBC Capital Markets
Goldman Sachs
Morgan Stanley
Barclays
BofA Securities
JPMorgan Chase
Credit Suisse
Citigroup
Argus
Alembic Global
Wolfe Research
J.P. Morgan Chase

Ratings for The Chemours Company

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar